I have all the content I need from the PDF extraction. Let me now create the full study guide.
π MEDICINAL CHEMISTRY OF ANTIHISTAMINES
Section B - SAQ & LAQ Master Study Guide
University of Cyberjaya | B. Pharm Year 1 Semester 2
π COMPLETE LEARNING OBJECTIVES TABLE
| # | Learning Objective | Exam Type | Marks Weight |
|---|
| 1 | Describe histamine's physiological roles and structure | SAQ | Medium |
| 2 | Explain histamine receptors (H1-H4) and their coupling | SAQ | Medium |
| 3 | Describe the chemistry and tautomerism of histamine | LAQ | High |
| 4 | Explain biosynthesis of histamine from histidine | SAQ | Medium |
| 5 | Describe binding of histamine to H1 receptor (3 stages) | LAQ | High |
| 6 | Explain the mechanism of action of H1 antihistamines (inverse agonism vs classic antagonism) | LAQ | High |
| 7 | Describe the general structural features of H1 antihistamines | LAQ | High |
| 8 | Classify antihistamines into 1st and 2nd generation with examples | SAQ | Medium |
| 9 | Explain why 2nd gen antihistamines are less sedating (BBB mechanism) | LAQ | High |
| 10 | Explain the role of zwitterion/internal salt formation in 2nd gen antihistamines | LAQ | High |
| 11 | Discuss loratadine metabolism and desloratadine as active metabolite | SAQ/LAQ | High |
π¬ OBJECTIVE 1 & 2: HISTAMINE - ROLES & RECEPTORS
Histamine Physiological Roles
| Role | Location | Effect |
|---|
| Allergic inflammation | Mast cells, basophils | Vasodilation, itch, bronchoconstriction |
| Gastric acid secretion | Stomach parietal cells | Stimulates HCl production |
| Neurotransmission | Brain (hypothalamus) | Wake-sleep regulation |
| Local immune response | Tissue level | Mediates inflammatory cascade |
π§ KEY BOLD TERMS: organic compound, endogenous ligand, allergic inflammation, gastric acid secretion, neurotransmission, local immune response
Histamine Receptors Table
| Receptor | Coupling | Location | Function |
|---|
| H1 | Gq | Smooth muscle, endothelium, brain | Allergic response, itch, bronchoconstriction |
| H2 | Gs | Gastric parietal cells | Gastric acid secretion |
| H3 | Gi | CNS (presynaptic) | Neurotransmitter regulation |
| H4 | Gi | Immune cells | Immune modulation |
π§ KEY BOLD TERMS: G-protein coupled receptors (GPCR), H1 to H4, endogenous ligand
π― MEMORY TRICK - Histamine Receptor Roles:
"Girls Go In In"
- H1 = Gq (Girls)
- H2 = Gs (Go)
- H3 = Gi (In)
- H4 = Gi (In)
Or remember functions: "Allergy, Acid, Neuro, Immune" = H1, H2, H3, H4
βοΈ OBJECTIVE 3: CHEMISTRY OF HISTAMINE & TAUTOMERISM
Structure of Histamine
| Structural Component | Description | Importance |
|---|
| Imidazole ring | Heterocyclic aromatic ring with 2 nitrogens | Bears the two tautomeric forms |
| Ethylamine side chain | Aliphatic amino group (-CHβ-CHβ-NHβ) | Essential for receptor binding |
| N1 (pros nitrogen) | One nitrogen of imidazole ring | Part of naming system |
| N3 (tele nitrogen) | Other nitrogen of imidazole ring | Part of naming system |
π§ KEY BOLD TERMS: imidazole ring, aliphatic amino group, ethylamine side chain, tautomeric forms, pros tautomer, tele tautomer
Tautomerism of the Imidazole Ring
| Tautomer | Protonated Nitrogen | Function |
|---|
| Tele tautomer (NΟ-H) | N3 (tele position) | Initial receptor binding form |
| Pros tautomer (NΟ-H) | N1 (pros position) | Receptor activation form |
The naming system is based on which of the two imidazole nitrogens is protonated
π― MEMORY TRICK - Tautomers:
"Tele = Triggers binding" (Tele tautomer binds FIRST)
"Pros = Powers activation" (Pros tautomer activates the receptor)
Think: "T before P" - just like the alphabet - Tele binds, then Pros activates
𧬠OBJECTIVE 4: BIOSYNTHESIS OF HISTAMINE
Biosynthesis Pathway
| Step | Details |
|---|
| Precursor | L-Histidine (naturally-occurring L-amino acid) |
| Reaction type | Decarboxylation (removal of -COOH group) |
| Enzyme 1 | Pyridoxal phosphate-dependent histidine decarboxylase |
| Enzyme 2 | L-aromatic amino acid decarboxylase |
| Product | Histamine |
π§ KEY BOLD TERMS: L-histidine, decarboxylation, pyridoxal phosphate, histidine decarboxylase, L-aromatic amino acid decarboxylase
π― MEMORY TRICK - Biosynthesis:
"His β His-tamine"
Histidine Decarboxylation β Histamine
Enzyme = "His Dec" (Histidine Decarboxylase) needs PLP (Pyridoxal Phosphate)
Remember: PLP = "Please Lose the Phosphate" (but actually it loses COβ - just the mnemonic sticks!)
π OBJECTIVE 5: H1 RECEPTOR BINDING - 3 STAGES
Key Amino Acids at H1 Receptor Binding Site
| Amino Acid | Position | Interaction |
|---|
| Aspartate (Asp107) | Position 107 | Ion-ion interaction with protonated amino group |
| Lysine (Lys191) | Position 191 | Hydrogen bonding with imidazole ring |
| Asparagine (Asn198) | Position 198 | Hydrogen bonding with imidazole ring |
π§ KEY BOLD TERMS: Asp107, Lys191, Asn198, ion-ion interaction, hydrogen bonding
Three Stages of H1 Receptor Binding
| Stage | Tautomer | Event |
|---|
| Stage 1: Initial Receptor Binding | Tele tautomer | Histamine docks to the receptor |
| Stage 2: Proton Transfer | Transition | Proton shifts from N3 to N1 |
| Stage 3: Receptor Activation | Pros tautomer | Conformational change activates the receptor |
π― MEMORY TRICK - 3 Stages:
"Bind, Transfer, Activate" = BTA (like a Business Travel Allowance - you get paid after you do the work!)
Or: "Tele Docks, Proton Walks, Pros Talks"
- Tele tautomer DOCKS (binds)
- Proton WALKS (transfers)
- Pros tautomer TALKS (activates = signals)
π OBJECTIVE 6: MECHANISM OF ACTION OF H1 ANTIHISTAMINES
Inverse Agonism vs Classic Antagonism
| Mechanism | Description | Most Common? |
|---|
| Inverse Agonism | Drug binds to inactive form of H1, stabilizing/shifting conformation toward the inactive state. Reduces basal receptor activity. | YES - majority of antihistamines |
| Classic Antagonism | Drug occupies the receptor and blocks histamine from binding, but does NOT shift receptor to inactive state | Less common |
π§ KEY BOLD TERMS: inverse agonism, inactive form, conformational change, classic antagonism, H1 antihistamines
π― MEMORY TRICK - Inverse Agonism:
"Antihistamines are INVERTERS" - they flip the switch OFF
Normal agonist = turns receptor ON
Inverse agonist = turns receptor MORE OFF than baseline
Classic antagonist = just BLOCKS the door (neutral)
Think: "Invert = Inverse Agonism" - most antihistamines do this!
ποΈ OBJECTIVE 7: GENERAL STRUCTURAL FEATURES OF H1 ANTIHISTAMINES
Classic Antihistamine Structure Template
| Structural Component | Role | Details |
|---|
| Aromatic moieties (ArΒΉ and ArΒ²) | Receptor affinity via van der Waals interactions | Increase lipophilicity; covalently bonded to X |
| X moiety (linking group) | Dictates the CLASS of antihistamine | Can be N, O, C |
| Spacer unit | Connects X to amino group | Generally unsubstituted, 2-3 carbons, can be a ring (e.g. piperazine) |
| Amino group (tertiary amine) | Ion-ion interaction with Asp107 | pKa ~8.5-9.5; cationic at physiological pH 7.4 |
π§ KEY BOLD TERMS: aromatic substituents, van der Waals interactions, lipophilicity, X moiety, spacer unit, piperazine, tertiary amine, pKa 8.5-9.5, cationic, physiological pH 7.4, Asp107
X Moiety - Classes of Antihistamines
| X Moiety | Class | Example Drug |
|---|
| Nitrogen (-N-) | Ethylenediamine class | Pyrilamine |
| Oxygen (-O-) | Ethanolamine class | Diphenhydramine |
| Carbon (-C-) | Propylamine/Alkylamine class | Chlorphenamine |
| Ring (piperazine) | Piperazine class | Cetirizine |
| Ring (phenothiazine) | Phenothiazine class | Promethazine |
Chirality and SAR (Structure-Activity Relationship)
| SAR Point | Details |
|---|
| Chirality at X | Can dictate antihistamine potency |
| S-enantiomers | Usually the eutomers (more pharmacologically active enantiomer) |
| Aromatic substituents | Increase lipophilicity and receptor affinity |
| Spacer | Unsubstituted, 2-3 carbons optimal |
| Tertiary amine | Greatest antihistaminic activity vs primary/secondary |
| Small alkyl groups | Preferred substituents on amino group (e.g. methyl) |
π§ KEY BOLD TERMS: chirality, eutomer, S-enantiomer, tertiary amine, lipophilicity, van der Waals, piperazine
π― MEMORY TRICK - Structural Features:
"2 Rings, X, Spacer, Amine" = the 4 components
Use the phrase: "Two ARs eXcite Spacemen And Amines"
- Two ARomatic rings
- X moiety (class determinant)
- Spacer (2-3 carbons)
- Amino group (tertiary, cationic at pH 7.4)
For eutomer: "S is Superior" = S-enantiomer = eutomer (more active)
π OBJECTIVE 8: CLASSIFICATION - 1ST vs 2ND GENERATION
1st vs 2nd Generation Comparison Table
| Feature | 1st Generation | 2nd Generation |
|---|
| Age | Older | Newer |
| CNS penetration | High (crosses BBB freely) | Low (poor BBB penetration) |
| Sedation | High - significant sedative effect | Minimal sedative effect |
| Polarity | Low polarity | High polarity (zwitterionic) |
| BBB mechanism | Lipophilic - crosses BBB | Zwitterion at physiological pH = increased polarity = cannot cross BBB |
| Examples | Chlorphenamine, Promethazine | Cetirizine, Loratadine, Fexofenadine |
| Selectivity | Less peripheral selective | More peripherally selective |
π§ KEY BOLD TERMS: first generation, second generation, CNS activity, peripherally selective, zwitterionic, blood-brain barrier (BBB), sedation, polarity, chlorphenamine, promethazine, cetirizine, loratadine
π― MEMORY TRICK - Classification:
"Old drugs are DROWSY, New drugs STAY AWAKE"
1st Gen = "Sleepy Oldies" (Chlorphenamine, Promethazine - you sleep/snore: Chlorphenamine Promethazine = CP = Causes Passout)
2nd Gen = "Alert and Zwitty" (Zwitterion = can't cross BBB = no sedation)
Remember: "Zwitterion = Zero CNS"
π OBJECTIVE 9 & 10: WHY 2ND GEN DON'T SEDATE - BBB MECHANISM
Zwitterion Formation and BBB Penetration
| Feature | Details |
|---|
| Zwitterionic at physiological pH | Both cetirizine and fexofenadine bear a carboxylic acid terminating the long chain AND a basic amino group β forms internal salt/zwitterion |
| Folded internal salt | At physiological pH, the amino group (protonated, +) and carboxylic acid (deprotonated, -) attract each other β molecule folds onto itself |
| Enhanced polar character | Internal salt has increased polarity = reduced lipophilicity = cannot traverse the lipophilic BBB |
| Reduced CNS transport | Folded form has lower affinity for CNS transport proteins β accumulates in periphery |
| Extended conformation at receptor | Upon binding to peripheral H1 receptors, fexofenadine adopts extended conformation β extra ion-ion interaction β enhanced peripheral binding |
π§ KEY BOLD TERMS: zwitterion, internal salt, carboxylic acid, folded conformation, extended conformation, polar character, blood-brain barrier (BBB), CNS transport proteins, peripherally selective, ion-ion interaction, Asp107
Fexofenadine - Extended Conformation Binding
| State | Conformation | Effect |
|---|
| In bloodstream | Folded (internal salt dominates) | Reduced CNS penetration |
| At peripheral H1 receptor | Extended | Extra ion-ion interaction with receptor = enhanced binding |
π― MEMORY TRICK - Zwitterion/BBB:
"FOLD to HIDE from the Brain, UNFOLD to FIGHT at the Periphery"
Think of it like a sleeping bag:
- When folded/packed = polar = can't cross the fatty BBB
- When unfolded/extended at the receptor = extra binding = stronger peripheral effect
For the zwitterion concept: "ZIP code = Zwitterion In Periphery" - the drug stays in the periphery because it zips up into a folded internal salt!
π OBJECTIVE 11: LORATADINE METABOLISM & DESLORATADINE
Loratadine Metabolism Summary
| Feature | Loratadine | Desloratadine |
|---|
| Type | Prodrug (orally administered, well-absorbed) | Active metabolite (more potent) |
| Absorption | Well-absorbed in GI tract | Formed after hepatic metabolism |
| Metabolism | Rapid first-pass hepatic metabolism | N/A |
| Enzymes involved | CYP3A4, CYP2D6, CYP1A1, CYP2C19 | N/A |
| Key structural difference | Has ethyl carbamate-type moiety | Absent ethyl carbamate moiety |
| CNS entry | Minimal | Does not readily enter CNS β minimal sedative effects |
| Pharmacological activity | Less potent | More potent than loratadine |
π§ KEY BOLD TERMS: loratadine, desloratadine, prodrug, active metabolite, first-pass hepatic metabolism, cytochrome P450, CYP3A4, CYP2D6, CYP1A1, CYP2C19, ethyl carbamate moiety, non-sedating
π― MEMORY TRICK - Loratadine Metabolism:
"Lora loses her CARBAMATE coat to become DES-loratadine"
- Loratadine = wearing a carbamate coat
- Desloratadine = "DES-robed" (coat removed = carbamate gone)
- Desloratadine = MORE potent but LESS sedating
For CYP enzymes: "3A4 is the BOSS" (CYP3A4 is the major enzyme), with helpers 2D6, 1A1, 2C19
Memory: "3-2-1 blast off!" = CYP3A4, CYP2D6, CYP1A1 (countdown to drug metabolism!)
πΊοΈ MASTER MEMORY TRICK - THE "ANTI-H" FRAMEWORK
Use this to answer ANY question on antihistamines:
A - Amine group (tertiary, pKa 8.5-9.5, cationic at pH 7.4, binds Asp107)
N - Note the X moiety (N, O, C = ethylenediamine, ethanolamine, propylamine)
T - Tautomers of histamine (Tele binds β Pros activates)
I - Inverse agonism (majority mechanism, stabilizes inactive receptor)
H - Historical difference (1st gen = sedating, 2nd gen = non-sedating)
β QUICK EXAM ANSWER TEMPLATES
SAQ: "What are the key structural features of H1 antihistamines?"
State: ArΒΉ-X-ArΒ² scaffold with spacer and tertiary amine. X determines class (N/O/C). Amine is cationic (pKa 8.5-9.5) at pH 7.4 - anchors to Asp107 via ion-ion interaction. Aromatic rings provide van der Waals interactions and lipophilicity. Spacer is 2-3 carbons, unsubstituted. S-enantiomers are eutomers. Tertiary amines show greatest activity.
LAQ: "Explain why second-generation antihistamines have minimal sedation"
State: 2nd gen are zwitterionic at physiological pH. Long flexible chains terminate with carboxylic acid. Internal salt (zwitterion) forms between the protonated amino group (+) and deprotonated carboxylate (-) β molecule folds. This increases polarity, reducing lipophilicity, preventing BBB traversal. The folded form also has lower affinity for CNS transport proteins, keeping drug in periphery. Example: cetirizine, fexofenadine. Fexofenadine additionally adopts extended conformation at peripheral H1 receptors for enhanced binding.
SAQ: "Describe the biosynthesis of histamine"
Histamine is derived from the L-amino acid histidine via decarboxylation (removal of carboxyl group). Catalysed by pyridoxal phosphate-dependent histidine decarboxylase OR L-aromatic amino acid decarboxylase.
LAQ: "Describe the three stages of histamine binding to H1 receptor"
Key binding amino acids: Asp107, Lys191, Asn198. Stage 1: Tele tautomer of histamine docks (initial receptor binding). Stage 2: Proton transfer from N3 (tele) to N1 (pros). Stage 3: Pros tautomer triggers receptor activation via conformational change. The amino group forms ion-ion interaction with Asp107; imidazole ring forms hydrogen bonds with Lys191 and Asn198.
LAQ: "Discuss loratadine as a prodrug"
Loratadine is well-absorbed orally and undergoes rapid first-pass hepatic metabolism by CYP3A4, CYP2D6, CYP1A1, and CYP2C19. The major metabolite desloratadine is more pharmacologically potent. Key structural difference: desloratadine lacks the ethyl carbamate moiety present in loratadine. Desloratadine does not readily enter the CNS β minimal sedative effects.
π― FINAL CHEAT SHEET - ALL BOLD KEYWORDS AT A GLANCE
| Topic | Must-Know Bold Keywords |
|---|
| Histamine structure | imidazole ring, ethylamine side chain, tele tautomer, pros tautomer |
| Histamine roles | allergic inflammation, gastric acid secretion, neurotransmission, local immune response |
| Receptors | GPCR, H1 (Gq), H2 (Gs), H3 (Gi), H4 (Gi), endogenous ligand |
| Biosynthesis | L-histidine, decarboxylation, pyridoxal phosphate, histidine decarboxylase |
| H1 binding | Asp107, Lys191, Asn198, tele tautomer, proton transfer, pros tautomer |
| MOA | inverse agonism, inactive conformation, classic antagonism |
| SAR | Ar-X-Ar scaffold, X moiety, tertiary amine, pKa 8.5-9.5, van der Waals, S-enantiomer, eutomer, piperazine, lipophilicity |
| Classification | 1st gen (sedating): chlorphenamine, promethazine; 2nd gen (non-sedating): cetirizine, loratadine, fexofenadine |
| 2nd gen BBB | zwitterion, internal salt, folded conformation, polar character, BBB, CNS transport proteins, extended conformation |
| Loratadine | prodrug, desloratadine, first-pass metabolism, CYP3A4/2D6/1A1/2C19, ethyl carbamate moiety |
π‘ Professor's Top 3 Exam Tips:
- Always explain the "WHY" - don't just state facts. E.g. "Zwitterion forms THEREFORE polarity increases THEREFORE cannot cross BBB"
- Connect structure to function - every SAR point must link to a pharmacological consequence
- Fexofenadine is a favourite LAQ trap - remember BOTH the folded (in blood) AND extended (at receptor) conformations and their different consequences